Author

Anna Manukyants

Observed name: A. Manukyants

Institution: Novartis (Switzerland)

Observed institution: Novartis (Switzerland)

OpenAlex ID: A5032533204

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial

2021 · Samuel Martel, Matteo Lambertini, et al. · Journal of the National Comprehensive Cancer Network · 27

Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.

2020 · P. Nuciforo, J. Townend, et al. · European Journal of Cancer · 3

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.

2018 · Samuel Martel, Matteo Lambertini, et al. · Journal of Clinical Oncology · 3

Pf499 Compliance and Clinical Benefit of Deferasirox Granule Formulation Vs Dispersible Tablets in Pediatric Patients With Transfusional Iron Overload: Results From the Phase Ii Calypso Study

2019 · A.T. Taher, Y. Wali, et al. · HemaSphere

Works count: 4

Citation count: 33

H-index: 3

I10-index: 1